Dopamine (3,4-dihydroxyphenylethylamine) is considered to be the immediate metabolic precursor of norepinephrine (1), from which it differs by the absence of a P-OH group. Despite this chemical similarity, previous studies of the action of dopamine (2-9) have demonstrated that many of the circulatory and metabolic effects of this catecholamine are different from those produced by norepinephrine. Horwitz, Fox, and Goldberg (6) observed that intravenous administration of dopamine to normal subjects produced consistent increases in cardiac output and either decreased or did not change peripheral resistance. Norepinephrine, on the other hand, decreases or does not change cardiac output and increases peripheral resistance in normal subjects (10). The circulatory effects of dopamine are potentiated by monoamine oxidase inhibitors to a much greater extent than are those of norepinephrine (9) . Dopamine also contrasts with norepinephrine in its failure to increase circulating free fatty acids (7, 8) . These differences suggest that the effects of
dopamine do not depend entirely upon conversion to norepinephrine.
Recently, Goldberg, McDonald, and Zimmerman (11) reported that sodium excretion was markedly increased after administration of dopamine to four patients with congestive heart failure. Since similar increases in sodium excretion have not been reported after administration of other sympathomimetic amines, it seemed desirable to define the specific properties of dopamine responsible for this action. The present investigation was designed to determine the effects of dopamine on the renal clearances of inulin and paraaminohippurate and on electrolyte and total solute excretion in normal subjects and in patients with congestive heart failure. Cardiac output was also measured in normal subjects to determine whether dopamine altered the fraction of the cardiac output perfusing the kidneys.
Methods
Normal subjects. All subjects were male and with the exception of M. Br., a graduate student, the volunteers were studied at the U. S. Federal Penitentiary, Atlanta, Ga. Ages ranged from 23 to 36 years with a mean age of 34 years. A common protocol with slight modifications was followed in each study. The volunteer was admitted to the ward on which the studies were being conducted. Laboratory tests, electrocardiogram, medical history, and physical examination were obtained on each subject. No subject had clinical evidence of cardiovascular or renal disease. Dopamine1 was administered intravenously as a dilute solution in 5% dextrose in water. The rate of infusion was controlled by a Harvard peristaltic infusion pump (model 600-1200). The dose of dopamine to be used was determined 2 days before the renal and cardiovascular studies by trial infusion. The dose to be used in the studies was the largest that could be infused without increasing mean arterial blood pressure. In a few subjects the dose so determined produced slight change in arterial pressure during the subsequent studies.
The subject was served the routine hospital diet, and no attempts were made to achieve electrolyte balance. Statistical methods. The data from the normal subjects were homogeneous in variance, permitting analysis by the paired t test (16) . This test, however, was unsuitable for the response of the patients in congestive heart failure because of the wide variability of response. In the latter group the presence of two subjects showing large responses suggests a skewness to the right. The high values of the positive responses of these patients increased the means and variances for the group, and the variance of the data varied with the magnitude of the mean. For these data the t test was applied more appropriately to the logarithms of the ratio: observation during dopamine infusion/ observation before dopamine infusion (17) .
The coefficient of variation (CV) (18) was calculated as 100 X square root of the within-subject mean square for a given experimental condition divided by the mean for the experimental condition. This indicates the relative variability of the clearance and excretion data. By comparison, our calculations of CV from the statistical data of Davies and Shock (19) yielded values of 7.0% for inulin clearance and 6.3% for Diodrast clearance.
Results
Effects of dopamine infusions in normnal subjects. The renal clearance and electrolyte excretion data are shown in Table I and graphically presented in Figure 1 . Typical effects in one subject are shown in Figure 2 . Glomerular filtration rate (GFR), effective renal plasma flow (ERPF), sodium excretion (UNaV), and osmolar clearance (Cosm) increased in each case studied and significantly in the group as a whole. Changes in potassium excretion (UKV) and urine flow were variable. Free water clearance decreased in each patient except M. B. and R. J. There was no significant change in serum sodium Effects of dopamine infusion in patients wvith congestive heart failure. Seven renal clearance and electrolyte excretion studies were performed on six patients (E. B. was studied on two occasions separated by a 10-day interval). These data are shown in Table III and Figure 4 . A correction for body surface area was not made because of the presence of edema and ascites in some of the patients. Without exception, dopamine infusion was associated with an increase in mean GFR, ERPF, Cosm, UNaV, and UKV. However, only the increase in sodium excretion was significant. This reflects the large CV in this -group of patients. The period-to-period variations in these patients are considerably larger than those obtained for the group of normal subjects.
The variation was probably in part attributable to the low urine flow, but may also reflect less physiological stability in this group. It is evident that urine volume increased most markedly in patients T. R. and E. B., no. 2. These higher flows were nearly constant after 40 minutes' equilibration, and the changes in clearance and excretion were not attributable to washout effect. Table IV summarizes the effects of dopamine on heart rate, mean arterial blood pressure, and pulse pressure in these studies. The responses to dopamine were quite variable and resembled the responses with the normal subjects in that no significant change in mean blood pressure or heart rate was observed. In contrast to the studies with the normal subjects, however, the pulse pressure was not significantly increased.
Side effects. Most of the subjects were aware of a more forceful beating of the heart during the dopamine infusions, but did not find this symptom distressing. Adverse effects were not observed during the dopamine infusions in which data were obtained. Typical angina pectoris, however, occurred in two patients (T. R. and J. B.) who were subject to angina on exertion, and an increased number of ventricular premature contractions occurred in a third patient (M. B.) at the time of initial infusions during which larger doses of dopamine were administered than were subsequently used during the renal clearance studies. These side effects were transitory and were relieved shortly after the dopamine infusions were .lr Figure 1 , except that values are not corrected for BSA.
FIG. 4. EFFECTS OF DOPAMINE IN PATIENTS WITH CONGESTIVE HEART FAIL-URE. Legend as in
discontinued. These experiences indicate that dopamine, like other sympathomimetic amines, should be administered cautiously to patients with possible myocardial ischemia in order to avoid the consequences of excessive elevations of blood pressure and myocardial stimulation.
Discussion
The consistent increases in GFR, ERPF, and UN.V produced by dopamine in normal subjects are in marked contrast to the effects previously found to occur in acute experiments with other sympathomimetic amines. The other naturally occurring catecholamines, epinephrine and norepinephrine, usually decrease ERPF and UNaV when administered in doses that increase arterial pressure (20) . When these catecholamines are administered in doses that produce minimal effects on blood pressure, ERPF frequently falls (21, 22) .
Sympathomimetic amines, such as ephedrine and metaraminol, also differ from dopamine in their acute effects in normal subjects. These amines occasionally produce moderate increments in UNaV, but do not significantly change ERPF or GFR (20, (23) (24) (25) . When these amines increased UNaV, they also increased mean arterial blood pressure. Accordingly, it is possible that the increments in sodium excretion were related to increased renal perfusion pressure (26) . The natriuresis produced by dopamine cannot be explained by such a mechanism, since it occurred without significant changes in mean arterial pressure. Isoproterenol and mephentermine have in a few instances been observed to increase ERPF, GFR, and UNaV in normal man (27) . This and their effect in increasing cardiac output (28, 29) resemble the effects of dopamine, but in patients with congestive heart failure significant increase in UNaV has not been observed. Sandler, Dodge, and Murdaugh (30) reported that the administration of isoproterenol to patients with congestive heart failure increased renal blood flow but did not increase sodium excretion significantly. The average increase in UNaV produced by isoproterenol was 37% as compared to 365% in the patients infused with dopamine. The renal fraction of cardiac output decreased in most of the patients after isoproterenol administration, indicating that vascular beds other than the renal took a more active role in the vasodilatation produced by this amine. These results are in agreement with animal studies which indicate that the principal site of the vasodilatation produced by isoproterenol is the skeletal muscle (31) . With regard to mephentermine, Frye, Kahler, and Braunwald (32) found that administration of this amine produced greater decompensation in three patients with cardiac insufficiency.
Of the agents that increase renal blood flow, the action of aminophylline is most like that of dopamine. In normal subjects (33) (34) (35) and in patients with congestive heart failure (35-37) aminophylline increases cardiac output, GFR, ERPF, and UNaV. Hydralazine increases cardiac output but, unlike dopamine, depresses arterial blood pressure and accelerates heart rate (38, 39) . Hydralazine increases ERPF in normal subjects (38, 39) , but its effect on GFR is uncertain (40, 41) . The renal fraction of cardiac output is decreased by this agent (38) . UNaV is not reported to be increased in normal subjects by hydralazine (42) , but a pronounced natriuresis occurs when this drug is administered to patients with hypertensive heart disease (38) . The systemic hemodynamic effects of pyrogen are similar to those produced by aminophylline and dopamine (43) .
UNaV and ERPF are increased in normal subjects, but GFR apparently does not increase (43, 44) .
The regular increase in the filtered load of sodium produced by dopamine in these experiments is sufficient to account for the increased UNaV. Clearance techniques in this experimental design lack the sensitivity required to evaluate the possible contribution of simultaneous changes in tubular reabsorption of sodium. The increase of ERPF may account for the increase in GFR in these studies. The increase in ERPF without an increase of perfusion pressure denotes a fall in total intrarenal resistance. Such a decrease in resistance can result from vasodilatation, the opening of shunts, or a change in the effective viscosity of the blood.
Recent studies on the dog in our laboratories throw some additional light on the mechanism of action of dopamine in decreasing intrarenal resistance. Dopamine infusions increase ERPF, GFR, and UNaV in the same order of magnitude as seen in man (45) . Administration of dopamine into the denervated renal artery of the dog, at doses not affecting systemic pressure, increases blood flow as measured by an electromagnetic flowmeter, indicating that the amine has a direct effect on renal resistance (46) . This action cannot be blocked by dichloroisoproterenol, as are the effects of isoproterenol, and, therefore, the effect does not appear to be the result of combination with 8-adrenergic receptors (47) . Other studies in the dog have shown that dopamine produces reflex reduction of resistance in the perfused limb (5). Accordingly, it is possible that the decreased renal resistance observed in man may be the result of both direct and reflex actions of dopamine. In the dog dopamine infusions decrease renal extraction of PAH (48) , a finding consistent with the possibility of a change in the intrarenal distribution of renal blood flow.
Dopamine's reduction of renal resistance in man suggests that this naturally occurring catecholamine may have a physiologic role in the regulation of renal blood flow. Speculations concerning a possible physiologic role for dopamine have been made by other investigators. Holtz (49) found high concentrations of dopamine in the intestine and lung and suggested that the amine may act as a nonneuronal transmitter substance. Carlsson (50) reported that there was a higher concentration of dopamine than norepinephrine in the corpus striatum and postulated that the amine may be involved in extrapyramidal function. More recently, Allwood, Cobbold, and Ginsburg (51) found that injection of dopamine into the brachial artery produced piloerection. Since a similar effect did not occur with epinephrine or norepinephrine, they suggested that dopamine may be involved in normal piloerector responses. The similar effects of dopamine on the ERPF, GFR, and UNV in normal man and patients in heart failure suggest that the mechanisms are the same in both states. The consistency of the response in heart failure is indicated by the increased UNaV observed in each of 12 patients to whom dopamine has now been administered (52). Summary 1) Dopamine, the biochemical precursor of norepinephrine, was infused intravenously into nine normal subjects and six patients with congestive heart failure.
2) Sodium excretion increased significantly in both normal subjects and patients with congestive heart failure.
3) Glomerular filtration rate and renal plasma flow also increased in normal subjects. 4) Hemodynamic studies in five normal subjects indicated that dopamine increased cardiac output and decreased peripheral resistance. The renal fraction of cardiac output did not change significantly. 5 ) These studies have shown that the renal effects of dopamine are different from those reported for other sympathomimetic amines.
